TScan Therapeutics, Inc. (TCRX) Fair Value 2026

TCRX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.4 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-27, TScan Therapeutics, Inc. (TCRX) trades at $0.75, versus a $1.78 median fair value across its 2 active models — 136.7% above the current price. QOC: 6.4/10. Value Trap Risk: 26/100 (LOW). 2/13 models active.

Key Facts

Ticker
TCRX
Price
$0.75
Quality Score
6.4/10
Value Trap Risk
26/100
Models Active
2/13
Last Updated
Strength: PWERM suggests +147.3% upside with 29% confidence
Risk: Limited model coverage (2/13) may reduce confidence

Is TScan Therapeutics, Inc. (TCRX) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, TScan Therapeutics, Inc. (TCRX) appears undervalued as of : the median of 2 independent fair value estimates is $1.78, 136.7% above the current price of $0.75. Estimates range from $1.70 to $1.86. TCRX scores 6.4/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. TCRX’s +136.7% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy TScan Therapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give TCRX?

2 Intrinsic Value Models vs. Current Price ($0.75)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $1.70 +126.2%
Option-Based · Medium Conviction
 $1.86 +147.3%

All Models Active

All 2 models are displayed above.

What Is TScan Therapeutics, Inc. (TCRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for TScan Therapeutics, Inc.. Trading at $0.75 against an estimated intrinsic value of $1.78, 2 of 2 active models flag meaningful upside of +136.7% at the median.

What Do the Models Say About TCRX?

2 of 13 models are currently active for TCRX. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for TCRX is $1.78 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does TCRX Rank in Biotechnology?

Among 620 Biotechnology stocks, TCRX ranks #107 by Quality of Company score. CirclFi's QOC score of 6.4/10 evaluates 32 fundamental signals. A score of 6.4 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, TScan Therapeutics, Inc. competes in an environment where partnership revenue often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is TCRX a Value Trap?

CirclFi's Value Trap algorithm assigns TCRX a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for TScan Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, TScan Therapeutics, Inc. is rated at 6.4/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

Models cluster within a tight range (+21.1% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TCRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TCRX's 2 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy TScan Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

IONSIonis Pharmaceuticals, Inc.QOC 6.4STROSutro Biopharma, Inc.QOC 6.3HRTXHeron Therapeutics, Inc.QOC 6.4CTMXCytomX Therapeutics, Inc.QOC 6.3MNOVMediciNova, Inc.QOC 6.4ASMBAssembly Biosciences, Inc.QOC 6.3AVIRAtea Pharmaceuticals, Inc.QOC 5.2AXIMAXIM Biotechnologies, Inc.QOC 4.6XCURExicure, Inc.QOC 3.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: IONS · STRO · HRTX · CTMX · MNOV · ASMB · AVIR · AXIM · XCUR · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to TCRX?

6 companies across all industries closest to TCRX’s Quality of Company score of 6.4/10.

SFLSFL Corporation Ltd.QOC 6.4FLGFlagstar Bank, National AssociationQOC 6.4KROKronos Worldwide, Inc.QOC 6.4TDSTelephone and Data Systems, Inc.QOC 6.4APYXApyx Medical CorporationQOC 6.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SFL · FLG · KRO · TDS · APYX · NVDA

Where Does TCRX Sit in CirclFi's Biotechnology Rankings?

TCRX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About TScan Therapeutics, Inc.’s Valuation?

What is TScan Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts TScan Therapeutics, Inc. (TCRX)'s intrinsic value at $1.78 — the median of 2 independent model estimates as of 2026-08-27, ranging from $1.70 to $1.86. The Quality of Company score is 6.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TCRX overvalued or undervalued right now?

At $0.75, 2 of 2 active models suggest TCRX may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $1.78, 136.7% above the current price of $0.75 — a consensus view that TCRX is undervalued. The assessment depends on which methodology best fits TScan Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.4 mean for TCRX?

TScan Therapeutics, Inc.'s QOC of 6.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on TCRX?

CirclFi analyzes TCRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is TCRX a value trap in 2026?

TScan Therapeutics, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, TScan Therapeutics, Inc. (TCRX) has a median fair value of $1.78 — 136.7% above the current price of $0.75 — as of 2026-08-27.” Source: circlfi.com/stock/TCRX/ · Methodology
Primary sources for this TCRX valuation
  • Financial statements: TScan Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001783328) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TCRX as of ; valuations recomputed .